Locomotor activity and motor disturbances induced by the competitive NMDA receptor antagonist CGP 37849

Polish Journal of Pharmacology

Volumn 48, Issue 5, 1996, Pages 467-479

  Kolasiewicz, Wacłlaw ^a   Maj, Jerzy ^a  

^a INSTITUTE OF PHARMACOLOGY   (Poland)

Author keywords

caudate putamen; CGP 37849; locomotor activity; motor disturbances; nucleus accumbens; SKF 525 A

Indexed keywords

2 AMINO 4 METHYL 5 PHOSPHONO 3 PENTENOIC ACID; N METHYL DEXTRO ASPARTIC ACID RECEPTOR BLOCKING AGENT; PROADIFEN;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; BRAIN REGION; CAUDATE NUCLEUS; CONTROLLED STUDY; DOSE TIME EFFECT RELATION; DRUG ANTAGONISM; DRUG POTENTIATION; HISTOLOGY; INTRACEREBRAL DRUG ADMINISTRATION; INTRAPERITONEAL DRUG ADMINISTRATION; LOCOMOTION; MALE; MICROINJECTION; MOTOR DYSFUNCTION; NONHUMAN; NUCLEUS ACCUMBENS; PUTAMEN; RAT;

2-AMINO-5-PHOSPHONOVALERATE; ANIMALS; CAUDATE NUCLEUS; DOSE-RESPONSE RELATIONSHIP, DRUG; ENZYME INHIBITORS; EXCITATORY AMINO ACID ANTAGONISTS; INJECTIONS, INTRAPERITONEAL; LOCOMOTION; MALE; MICROINJECTIONS; MOTOR ACTIVITY; NUCLEUS ACCUMBENS; PROADIFEN; PUTAMEN; RATS; RATS, WISTAR; RECEPTORS, N-METHYL-D-ASPARTATE;

EID: 0030450712     PISSN: 12306002     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (25)

1. Carlsson M., Carlsson A.: The NMDA antagonist MK-801 causes marked locomotor stimulation in monoamine-depleted mice. J. Neural Transm., 1989, 75, 221-226.
2. Carlsson M., Carlsson A.: Dramatic synergism between MK-801 and clonidine with respect to locomotor stimulatory effect in monoamine-depleted mice. J. Neural Transm., 1989, 77, 65-71.
3. Carlsson M., Svensson A.: Interfering with glutamatergic neurotransmission by means of NMDA antagonist administration discloses the locomotor stimulatory potential of other transmitter system. Pharmacol. Biochem. Behav., 1990, 36, 45-50.
4. Clineschmidt B. V., Martin G. E., Bunting P. R., Papp N. L.: Central sympathomimetic activity of (+)-5-methyl-10,11-dihydro-5H-dibenzo[a,d]cyclohepten5,10- imine (MK-801), a substance with potent anticonvulsant, central sympathomimetic, and apparent anxiolytic properties. Drug Develop. Res., 1982, 2, 135-145.
5. Fagg G. E., Olpe H.-R., Pozza M. F., Baud J., Steinman M., Schmutz M., Portrt C., Baumann P., Thedinga K., Bittiger H., Allgeier H., Hackendorn R., Angst C., Bmndish D., Dingwall J. G.: CGP 37849 and CGP 37551: novel and potent competitive antagonists with oral activity. Brit. J. Pharmacol., 1990, 99, 791-797.
6. Huffman D. C.: Typical and atypical neuroleptics antagonize MK-801 -induced locomotion and stereotypy in rats. J. Neural Transm. [Gen. Sect.], 1992, 89, 1-10.
7. Kannari K., Markstein R.: Dopamine agonist potentiate antiakinetic effects of competitive NMDA-antagonists in monoamine-depleted mice. J. Neural Transm. [Gen. Sect.], 1991, 84, 211-220.
8. Klockgether T., Turski L.: NMDA antagonist potentiated antiparkinsonian actions of L-DOPA in monoamine-depleted rats. Ann. Neurol., 1990, 28, 539-546.
9. Koek W., Woods J. H., Winger G. D.: MK-801, proposed non-competitive antagonist of excitatory amino acid neurotransmission, produces phencyclidine-like behavioral effects in pigeon, rats and rhesus monkeys. J. Pharmacol. Exp. Ther., 1988, 245, 969-974.
10. Kolasiewicz W., Sauss C., Block F., Sontag K.-H.: Behavioural effects after cholinergic stimulation of the reticular thalamic nucleus in rats. J. Neural Transm. [Gen. Sect.], 1992, 87, 163-173.
11. Kretschmer B. D., Zadow D., Volz T. L., Schmidt W. J.: The contribution of the different binding sites of the N-methyl-D-asparate (NMDA) receptor to the expression of behaviour. J. Neural Transm. [Gen. Sect.], 1992. 87, 23-35.
12. Löscher W., Annies R., Honack D.: Comparison of competitive and uncompetitive NMDA receptor antagonist with regard to monoamine neuronal activity and behavioural effects in rats. Eur. J. PharmacoL, 1993. 242, 263-274.
13. Löscher W., Honack D.: The novel competitive N-methyl-D-asparate (NMDA) antagonist CGP 37849 preferentially induces phencyclidine-like behavioral effects in kindled rats: attenuation by manipulation of dopamine, alpha-1 and serotonin 1A receptors. J. Pharmacol. Exp. Ther., 1991, 257, 1146-1153.
14. Maj J., Rogóż Z., Skuza G.: Locomotor hyperactivity induced by MK-801 in rats. Pol. J. Pharmacol. Pharm., 1991, 43, 449-458.
15. Maj J., Skuza G., Rogóż Z.: Some central effects of CGP 37849 and CGP 39551, the competitive NMDA receptor antagonists: potential antiparkinsonian activity. J. Neural Transm. [P-D Sect.], 1993, 6, 53-62.
16. Papp M., Moryl E.: Antidepressant activity of noncompetitive and competitive NMDA receptor antagonists in a chronic mild stress model of depression. Eur. J. Pharmacol., 1994, 263, 1-7.
17. Paxinos G., Watson C., (Ed.): The Rat Brain in Stereotaxic Coordinates., 2. ed., Academic Press, Sydney, 1986.
18. Porter R. J.: Mechanism of action of new antiepileptic drugs. Epilepsia, 1989, 30, S29.
19. Pozza M. F., Olpe H., Brugger F., Fagg G. R: Electrophysiological characterization of a novel potent and orally active NMDA receptor antagonist: CGP 37849 and its ethyl ester CGP 37551. Eur. J. Pharmacol., 1990, 182, 91-100.
20. Schmidt W. J., Bubser M.: Anticataleptic effect of the N-methyl-D-aspartate antagonist MK-801 in rats. Pharmacol. Biochem. Behav., 1989, 32, 621-623.
21. Schmidt W. J., Zadow B., Kretschmer B. D. Hauber W.: Anticataleptic potencies of glutamate-antagonists. Amino Acids, 1991, 1, 225-237.
22. Schmutz M., Portet C., Jeker A., Klebs K., Vassout A., Allegeier R, Heckendorn R., Fagg G. E., Olpe H.-R., Van Riezen H.: The competitive NMDA receptor antagonists CGP 37849 and CGP 39551 are potent, orally-active anticonvulsants in rodents. NaunynSchmied. Arch. Pharmacol., 1990, 342, 61-66.
23. 3H] CGP 39653: a new N-methyl-D-aspartate antagonist radioligand with low nanomolar affinity in rat brain. Eur. J. Pharmacol., 1991, 192, 19-24.
24. Tiedtke P. J., Bischoff C., Schmidt W. J.: MK-801-induced stereotypy and its antagonism by neuroleptic drugs. J. Neural Transm. [Gen. Sect.], 1990, 81, 173-182.
25. Trullas R., Skolnick P.: Functional antagonists at the NMDA receptor complex exhibit antidepressant actions. Eur. J. Pharmacol., 1990, 185, 1-10.